| 21.97 -0.45 (-2.01%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.63  |
1-year : | 29.37 |
| Resists | First : | 23.66 |
Second : | 25.14 |
| Pivot price | 22.8  |
|||
| Supports | First : | 21.26 |
Second : | 17.68 |
| MAs | MA(5) : | 22.22 |
MA(20) : | 22.92 |
| MA(100) : | 20.65 |
MA(250) : | 19.69 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 17.3 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 25.14 | Low : | 16.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INVA ] has closed above bottom band by 17.3%. Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.45 - 22.54 | 22.54 - 22.64 |
| Low: | 21.91 - 22.01 | 22.01 - 22.1 |
| Close: | 22.26 - 22.43 | 22.43 - 22.6 |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Tue, 10 Mar 2026
How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations - simplywall.st
Wed, 04 Mar 2026
Innoviva, Inc. $INVA Shares Bought by Royce & Associates LP - MarketBeat
Mon, 02 Mar 2026
Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva (INVA) - simplywall.st
Sat, 28 Feb 2026
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why - Bitget
Sat, 28 Feb 2026
Innoviva, Inc. (INVA): A Bull Case Theory - Yahoo Finance
Fri, 27 Feb 2026
Cantor Fitzgerald Maintains Overweight on INVA Innoviva, Inc Feb 26 2026 - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 107 (%) |
| Shares Short | 6,720 (K) |
| Shares Short P.Month | 6,000 (K) |
| EPS | 3.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.71 |
| Profit Margin | 65.9 % |
| Operating Margin | 34.6 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 29.1 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 4.16 |
| Sales Per Share | 5.55 |
| EBITDA (p.s.) | 2.63 |
| Qtrly Earnings Growth | 590.4 % |
| Operating Cash Flow | 197 (M) |
| Levered Free Cash Flow | 122 (M) |
| PE Ratio | 6.65 |
| PEG Ratio | 0 |
| Price to Book value | 1.39 |
| Price to Sales | 3.95 |
| Price to Cash Flow | 8.26 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 1.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|